Free Newsletter
New Vytorin study not enough of a lift
Free newsletter via e-mail
Tools
Has Vytorin been wrongly maligned? A study presented last week appeared to suggest that it had. But Forbes' Matthew Herper looks at the evidence--and talks to the experts--to find that the latest data isn't enough of a shot in the arm. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: